ISDA

Deposition Date 2016-03-29

Release Date 2016-05-04

Last Version Date 2024-01-10

Entry Detail

PDB ID:

5J1V

Keywords:

TRANSFERASE

Title:

Crystal structure of human CLK1 in complex with pyrido[3,4-g]quinazoline derivative ZW29 (compound 13)

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli BL21(DE3)

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.52 Å

R-Value Free:

0.24

R-Value Work:

0.19

R-Value Observed:

0.20

Space Group:

P 1 21 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Dual specificity protein kinase CLK1
Gene (Uniprot):CLK1
Chain IDs:A, B, C
Chain Length:339
Number of Molecules:3
Biological Source:Homo sapiens

UniProt ID:P49759 Pfam ID:PF00069 EC:2.7.12.1

Ligand Molecules

6FD

GOL

Primary Citation

Discovery of pyrido[3,4-g]quinazoline derivatives as CMGC family protein kinase inhibitors: Design, synthesis, inhibitory potency and X-ray co-crystal structure.

Esvan, Y.J, Zeinyeh, W, Boibessot, T, Nauton, L, Thery, V, Knapp, S, Chaikuad, A, Loaec, N, Meijer, L, Anizon, F, Giraud, F, Moreau, P.Show

Eur.J.Med.Chem. 118 170 177 (2016)

PMID: 27128181 DOI: 10.1016/j.ejmech.2016.04.004

Abstact

The design and synthesis of new pyrido[3,4-g]quinazoline derivatives is described as well as their protein kinase inhibitory potencies toward five CMGC family members (CDK5, CK1, GSK3, CLK1 and DYRK1A). The interest for this original tricyclic heteroaromatic scaffold as modulators of CLK1/DYRK1A activity was validated by nanomolar potencies (compounds 12 and 13). CLK1 co-crystal structures with two inhibitors revealed the binding mode of these compounds within the ATP-binding pocket.

Legend

Protein

Chemical

Disease

Primary Citation of related structures